Viyash Scientific Limited (VIYASH)
₹226.00 +0.03% last close, 16 Oct
Latest quarterly results (Q4 FY26)
In its latest reported quarter, Q4 FY26, Viyash Scientific's revenue was ₹920 Cr (+128.9% year on year, +7.2% on the previous quarter), and net profit ₹66.0 Cr (+560.0% year on year); the operating margin was 20.0%.
| Q4 FY26 (₹ Cr) | Value | YoY vs Q4 FY25 | QoQ |
|---|---|---|---|
| Revenue | ₹920 | +128.9% | +7.2% |
| Operating profit | ₹184 | +300.0% | +4.8% |
| Net profit | ₹66.0 | +560.0% | +36.0% |
| EPS (₹) | 1.19 | +221.6% | +33.7% |
| Operating margin | 20.0% | — | — |
VIYASH delivery percentage
NSE end-of-day data for
On Fri, 16 Oct 2026, 48.77% of the VIYASH shares traded on NSE were taken to delivery, against the stock's own 20-session average of 53.21%. That is close to its usual level.
Delivery in the last 5 sessions: 44.3% · 43.3% · 68.8% · 50.7% · 48.8%
A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed
📢 Recent Corporate Announcements
Viyash Scientific Limited, through its step-down subsidiary Alivira Animal Health Limited (Ireland), has completed the 100% acquisition of Milan-based BioForLife Italia S.r.l. on October 1, 2026. The upfront base consideration stands at EUR 15.0 million plus the agreed reference net financial position as of June 30, 2026. A deferred consideration of EUR 1.976 million remains payable subject to final net financial position adjustments. Total consideration stands at approximately EUR 16.98 million, integrating the Italian animal health entity into Viyash's global business.
- Acquired 100% share capital of BioForLife Italia S.r.l. (Milan, Italy) effective October 1, 2026
- Base purchase consideration paid on closing is EUR 15.0 million plus reference net financial position
- Balance deferred consideration of EUR 1.976 million payable subject to closing adjustments
- Representatives of Alivira Animal Health Limited appointed to the Board of BFL Italy
Viyash Scientific Limited approved the allotment of 11,07,309 equity shares of face value Rs 2 each pursuant to the exercise of employee stock options on September 18, 2026. This comprises 9,26,333 shares at Rs 86 per share under the Sequent ESOP 2020 and 1,80,976 shares at Rs 101 per share under the Viyash ESOP 2026. The allotment expands the total issued and paid-up share capital from 44,05,20,361 shares (Rs 88.10 crore) to 44,16,27,670 shares (Rs 88.33 crore). Dilution from this event is minimal at approximately 0.25% of the pre-allotment equity base.
- Allotment of 11,07,309 fully paid-up equity shares of face value Rs 2 each
- 9,26,333 shares allotted at Rs 86 per share under Sequent ESOP 2020
- 1,80,976 shares allotted at Rs 101 per share under Viyash ESOP 2026
- Paid-up share capital increased from Rs 88,10,40,722 to Rs 88,32,55,340
Viyash Scientific Limited announced that its step-down wholly owned subsidiary, Alivira Animal Health Limited (Ireland), has received Italian FDI/Golden Power regulatory approval for acquiring 100% of BioForLife Italia S.r.l. Following this clearance, the transaction timeline has been revised to complete within two months from September 08, 2026. All other material terms from previous disclosures dated June 8 and July 21, 2026 remain unchanged, though deal value was not disclosed in this filing. The company generated TTM revenue of ₹1,854 crore and net profit of ₹121 crore.
- Received requisite Italian FDI / Golden Power regulatory approval from Italian authorities
- Acquisition covers 100% shareholding in Milan-based BioForLife Italia S.r.l.
- Target closing timeline revised to complete within two months from September 08, 2026
- Acquisition being executed via step-down wholly owned subsidiary Alivira Animal Health Limited, Ireland
Viyash Scientific Limited has approved the allotment of 6,12,773 equity shares of face value Rs. 2 each upon exercise of employee stock options. The allotment includes 2,30,001 shares at Rs. 86 per share under Sequent ESOP 2020 and 3,82,772 shares at Rs. 101 per share under Viyash ESOP 2026. Consequently, the company's paid-up equity share capital increases from Rs. 87.98 crore (43,99,07,588 shares) to Rs. 88.10 crore (44,05,20,361 shares), representing a minor dilution of approximately 0.14%.
- Allotment of 6,12,773 equity shares of face value Rs. 2 each approved on September 04, 2026
- 2,30,001 shares allotted at an exercise price of Rs. 86 per share under Sequent ESOP 2020
- 3,82,772 shares allotted at an exercise price of Rs. 101 per share under Viyash ESOP 2026
- Total paid-up equity share count increases from 43,99,07,588 to 44,05,20,361 shares (0.14% dilution)
Viyash Scientific reported strong Q1 FY27 performance following the completion of its integration, with revenue increasing 19.5% YoY to ₹946 crore. EBITDA surged 59.2% YoY to ₹205 crore as EBITDA margins expanded by ~530 bps to 21.6%. Net profit more than doubled, rising 115% YoY to ₹79 crore, absorbing an incremental ESOP cost of ₹19 crore. The balance sheet strengthened significantly with net debt falling to ₹86 crore (Net Debt/EBITDA of 0.1x).
- Revenue from operations grew 19.5% YoY to ₹946 crore with gross margins reaching 54.1%.
- Adjusted EBITDA rose 59.2% YoY to ₹205 crore, reflecting an EBITDA margin of 21.6%.
- Net profit stood at ₹79 crore (+115% YoY) after accounting for a ₹19 crore non-cash ESOP expense.
- Net debt reduced to ₹86 crore, reducing leverage to 0.1x Net Debt/EBITDA compared to ~1x a year earlier.
- Signed definitive SPA to acquire Bio For Life in Italy, adding direct access to 85 companion animal products and 85% vet clinic coverage.
Viyash Scientific Limited (formerly Sequent Scientific) has released the audio recording of its earnings call held on August 12, 2026. The call pertains to the unaudited financial results for the quarter ended June 30, 2026. This disclosure is a standard regulatory requirement following the company's significant scale-up, with TTM revenue now at Rs 976 Cr compared to FY25 revenue of Rs 136.27 Cr. Investors can access the recording via the company's website to understand management's commentary on recent performance and future outlook.
- Earnings call conducted on August 12, 2026, for the quarter ended June 30, 2026
- Company reported a significant TTM revenue of Rs 976 Cr as of the latest financial context
- Market capitalization stands at Rs 17,477 Cr with a high P/E ratio of 295.2
- Disclosure made in compliance with Regulation 30 of SEBI (LODR) Regulations, 2015
Viyash Scientific reported a robust Q1 FY27 with consolidated revenue of ₹946.4 Cr, a 19.5% YoY increase. Profitability saw a significant boost as EBITDA grew 59.2% YoY to ₹204.7 Cr, driven by a 530 bps margin expansion to 21.6%. The company is also expanding its European footprint through the acquisition of Bio For Life in Italy, targeting the companion animal market. Financial health remains strong with Net Debt to EBITDA at a minimal 0.1x.
- Consolidated Revenue reached ₹946.4 Cr in Q1 FY27, a 19.5% YoY increase from ₹791.6 Cr.
- EBITDA (adjusted for ESOP) rose to ₹204.7 Cr, representing a 59.2% YoY growth.
- Operating margins improved significantly by 530 bps YoY to reach 21.6%.
- Formulations revenue grew 33% YoY to ₹554.7 Cr, now comprising approximately 58% of total sales.
- Net Debt reduced to ₹86.1 Cr, bringing the Net Debt/EBITDA ratio down to 0.1x from 0.2x in Q4 FY26.
Viyash Scientific Limited (formerly Sequent Scientific) concluded its 41st Annual General Meeting on August 11, 2026, with all six proposed resolutions passed by the requisite majority. Key approvals included the adoption of FY26 audited financial statements and the re-appointment of directors Dr. Haribabu Bodepudi and Mr. Rajaram Narayanan. While the adoption of new Articles of Association passed with 97.98% overall support, it faced notable opposition from public institutions, with 30.79% of their votes cast against the resolution. The company maintains a stable promoter holding of 61.31% and reported TTM revenue of Rs 976 Cr.
- Total of 133,984 shareholders were on record as of the August 4, 2026 cut-off date
- Resolution for adoption of new Articles of Association passed with 97.98% total votes in favor
- Public institutional dissent was significant for the new Articles of Association at 30.79% of votes polled in that category
- Re-appointment of Director Dr. Haribabu Bodepudi secured 99.86% total approval
- Adoption of FY26 financial statements received near-unanimous support at 99.99% in favor
Viyash Scientific Limited (formerly Sequent Scientific) passed all six resolutions at its 41st AGM on August 11, 2026. Key approvals included the adoption of FY26 financial statements (Revenue: Rs 933.51 Cr, PAT: Rs 54.97 Cr) and the re-appointment of two directors. While all resolutions passed, Resolution 6 regarding the adoption of new Articles of Association saw a notable 30.79% of institutional votes cast against it. The company maintains a high P/E of 293.8, reflecting significant market expectations relative to its current earnings.
- All 6 resolutions passed at the 41st AGM held on August 11, 2026.
- Resolution 6 (New Articles of Association) faced 30.79% opposition from public institutional voters.
- Company reported FY26 revenue of Rs 933.51 Cr and net profit of Rs 54.97 Cr.
- Total shareholder count stood at 133,984 as of the August 4, 2026 cut-off date.
Viyash Scientific reported a robust Q1 FY27 with consolidated revenue rising 19.5% YoY to ₹946.4 crore. Profitability significantly outperformed revenue growth, with PAT surging 114.9% to ₹79.3 crore, supported by EBITDA margin expansion to 21.6% from 16.2% in the previous year. The company maintains a very strong balance sheet with a Net Debt/EBITDA ratio of 0.1x. Additionally, the company is expanding its European footprint through the acquisition of Bio For Life in Italy, targeting the companion animal segment.
- Consolidated Revenue increased by 19.5% YoY to ₹9,464 Million (₹946.4 Cr)
- EBITDA (excluding ESOP costs) grew by 59.2% to ₹2,047 Million
- Net Profit (PAT) surged by 114.9% to ₹793 Million (₹79.3 Cr)
- EBITDA margins expanded by 540 basis points to reach 21.6%
- Net Debt / EBITDA remains highly conservative at 0.1x
Viyash Scientific has approved the conversion of a Rs 400.02 Cr intercompany loan into equity for its wholly-owned subsidiary, Alivira Animal Health Limited (AAHL), to strengthen its capital structure and reduce interest costs. The company is also expanding internationally by incorporating a subsidiary in Vietnam with an initial investment of up to USD 400,000. Additionally, the board approved the allotment of 10,30,775 equity shares under its 2026 ESOP scheme at an exercise price of Rs 101 per share. AAHL remains a critical driver for the company, reporting a FY26 turnover of Rs 449.45 Cr, which is approximately 46% of the group's TTM revenue.
- Conversion of Rs 400.02 Cr intercompany loan into equity for subsidiary Alivira Animal Health Limited (AAHL)
- Allotment of 10,30,775 equity shares under ESOP 2026 at an exercise price of Rs 101 per share
- Planned investment of up to USD 400,000 for a new step-down subsidiary in Vietnam
- AAHL FY26 turnover grew to Rs 449.45 Cr from Rs 368.14 Cr in FY25
- Total paid-up equity capital increased to 43,99,07,588 shares of Rs 2 each
Viyash Scientific approved a major capital restructuring of its 100% subsidiary, Alivira Animal Health Limited (AAHL), by converting a Rs 400.02 Cr intercompany loan into equity to reduce interest burden. The company also announced its entry into Vietnam with a new step-down subsidiary and an initial investment of up to USD 400,000. Additionally, the board allotted 10.31 lakh equity shares under its 2026 ESOP scheme at Rs 101 per share. These moves follow a period of significant growth for AAHL, which saw its turnover rise to Rs 449.45 Cr in FY26.
- Conversion of Rs 400.02 Cr intercompany loan into equity for subsidiary AAHL to strengthen its capital structure.
- Planned investment of up to USD 400,000 for the incorporation of a new subsidiary in Vietnam.
- Allotment of 10,30,775 equity shares at Rs 101 per share under the ESOP Scheme 2026.
- AAHL reported a turnover of Rs 449.45 Cr for FY26, representing approximately 46% of Viyash's TTM consolidated revenue.
- Paid-up equity share capital increased from Rs 87.77 Cr to Rs 87.98 Cr following the ESOP allotment.
Viyash Scientific Limited has scheduled its Q1 FY27 earnings conference call for August 12, 2026, at 3:30 PM IST. The call will feature the Managing Director, CEO of Animal Health, and the CFO to discuss financial results for the quarter ended June 30, 2026. This follows a period where the company saw a significant revenue jump to ₹858.41 Cr in the Dec 2025 quarter. Investors will likely seek clarity on the sustainability of recent growth and the integration of the Animal Health business, given the high P/E ratio of 298.9.
- Earnings conference call scheduled for August 12, 2026, at 3:30 PM IST
- Discussion to cover financial results for the quarter ended June 30, 2026
- Key speakers include Dr. Hari Babu Bodepudi (MD & Group CEO) and Mr. Rajaram Narayanan (CEO - Animal Health)
- Company reported TTM revenue of ₹976 Cr and TTM PAT of ₹59 Cr
- Current market capitalization stands at ₹17,693 Cr with a P/E of 298.9
Viyash Scientific Limited has approved the allotment of 20,01,336 equity shares to employees under the SeQuent ESOP 2020 plan. The shares were issued at an exercise price of Rs 86 per share, which represents a significant discount to the current market price of Rs 257.1. This allotment results in a marginal equity dilution of approximately 0.46% for existing shareholders. The total paid-up equity capital of the company has increased to Rs 87.77 crore following this transaction.
- Allotment of 20,01,336 equity shares of face value Rs 2 each
- Exercise price fixed at Rs 86 per share, compared to the current market price of Rs 257.1
- Total paid-up equity share capital increased from Rs 87,37,50,954 to Rs 87,77,53,626
- Total number of equity shares increased to 43,88,76,813 post-allotment
- Equity dilution resulting from this specific allotment is approximately 0.46%
Viyash Scientific Limited, through its Irish subsidiary Alivira Animal Health, has executed a definitive Sale and Purchase Agreement (SPA) to acquire 100% of BioForLife Italia s.r.l. for EUR 16.976 million. The deal structure includes an upfront payment of EUR 15.0 million and a deferred consideration of EUR 1.976 million linked to contractual conditions. At current exchange rates, the deal value is approximately Rs 154 crore, representing roughly 15.8% of the company's TTM revenue of Rs 976 crore. The transaction is now pending Italian FDI (Golden Power) clearance.
- Total base consideration fixed at EUR 16.976 million for 100% equity acquisition
- Upfront cash payment of EUR 15.0 million to be paid at the time of closing
- Deferred consideration of EUR 1.976 million tied to specific contractual-continuation conditions
- Deal value represents approximately 15.8% of Viyash's TTM revenue of Rs 976 crore
- Completion is subject to Italian FDI / Golden Power regulatory clearance
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
